An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus streptomycin + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a randomized control trial

Table 3 Total sample sizes (both arms) for confirmed/probable bubonic cases

Therapeutic response*	Margin (%), unilateral confidence interval of 2.5%, loss of 10%, power 90%
Therapeutic response*	5	6	7	8	9	10	11	12	13	14	15
0.95	890	618	454	348	276	224	186	156	134	114	100
0.90	1684	1170	858	658	520	424	350	294	250	216	190
0.85	2384	1656	1216	932	736	596	494	416	354	306	268
0.80	2990	2076	1528	1170	926	750	618	520	444	384	334
0.75	3506	2434	1790	1370	1084	878	726	610	520	450	392

*Proportion of “therapeutic response” in the streptomycin and ciprofloxacin group

ISSN: 1745-6215